Safety and Efficacy Study of Femara(Letrozole) as an Extended Adjuvant Treatment in Breast Cancer Patients

Inclusion Criteria

• •Written informed consent form
• •Postmenopausal patients who had had a histologically or cytologically confirmed breast cancer removed at the time of diagnosis with no evidence of metastases and who had completed over 5 years of adjuvant therapy with tamoxifen or toremifen before entering the study
• •Age ≥50 years with cessation of menses and Age \<50 years Postmenopausal status defined by one of the following:
• •* FSH level \> 30-40 IU/L
• •* cessation of menses over the past 1 year
• •* are/become amenorrheic due to either chemotherapy or LHRH, are/become amenorrheic due to surgical ovarian ablation
• •The tumor was to be ER and/or PgR-positive or the receptor status could have been unknown
• •No evidence of recurrence of the disease at entry
• •Patient must be accessible for follow-up